Igor Gorbatchevsky, MD

Igor Gorbatchevsky's Title

Dr. Igor Gorbatchevsky currently holds the prestigious position of Chief Medical Officer. In this role, he leverages his extensive background in oncology drug development to oversee clinical strategies and ensure the medical integrity of the organization's research initiatives. His position places him at the forefront of clinical innovation, where he guides therapeutic advancements from conception through clinical trials to market approval.

Igor Gorbatchevsky's Company

Dr. Igor Gorbatchevsky has made significant contributions to several major biopharmaceutical companies throughout his career. He served as the Vice President of Clinical Development at MEI Pharma, where he was instrumental in advancing the company's oncology pipeline. Additionally, he held the position of Vice President of Clinical Science at Iovance Biotherapeutics, focusing on the development of novel cancer immunotherapies. His roles at these companies underscore his expertise in leading clinical programs and driving the successful development of innovative cancer treatments.

Igor Gorbatchevsky's Experience

With over two decades of direct experience in oncology drug development, Dr. Igor Gorbatchevsky has a robust track record in the biopharmaceutical industry. He has held senior leadership roles at prominent companies, including Global Clinical Leader at Bayer Pharmaceuticals and Senior Medical Director at Daiichi-Sankyo. Notably, he led the global clinical development team for ALIQOPA at Bayer, a pan-PI3K inhibitor that received FDA approval for treating follicular lymphoma. This extensive background highlights his capability to navigate the complexities of drug development and regulatory approval processes.

Igor Gorbatchevsky's Education and Expertise

Dr. Igor Gorbatchevsky received his medical training from the Omsk State Medical Academy. He further specialized in clinical immunology at the Chelyabinsk State Medical Academy. His educational background laid a solid foundation for his career in oncology, providing him with in-depth knowledge and clinical skills. His expertise spans a broad range of tumor types, both in adult and pediatric populations, making him a versatile and highly knowledgeable clinician and researcher in the field of oncology.

Igor Gorbatchevsky's Achievements

Among Dr. Igor Gorbatchevsky's notable achievements is his leadership in the development of ALIQOPA (copanlisib), a pan-PI3K inhibitor that obtained FDA approval for the treatment of patients with follicular lymphoma. This achievement is a testament to his proficiency in clinical development and his ability to guide complex projects to successful outcomes. His career is marked by numerous instances of advancing cutting-edge oncology treatments, cementing his reputation as a key figure in the field of cancer therapy development.